Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Receivables - Other (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed Receivables - Other for 6 consecutive years, with $20.0 million as the latest value for Q1 2025.

  • For Q1 2025, Receivables - Other rose 900.0% year-over-year to $20.0 million; the TTM value through Mar 2025 reached $20.0 million, up 900.0%, while the annual FY2024 figure was $900000.0, 76.32% down from the prior year.
  • Receivables - Other hit $20.0 million in Q1 2025 for Kymera Therapeutics, up from $900000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $20.0 million in Q1 2025 and bottomed at $135000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $3.3 million, with a median of $2.0 million recorded in 2024.
  • Year-over-year, Receivables - Other crashed 84.23% in 2021 and then skyrocketed 1779.26% in 2022.
  • Kymera Therapeutics' Receivables - Other stood at $135000.0 in 2021, then surged by 1779.26% to $2.5 million in 2022, then skyrocketed by 49.78% to $3.8 million in 2023, then tumbled by 76.32% to $900000.0 in 2024, then surged by 2122.22% to $20.0 million in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $20.0 million, $900000.0, and $1.3 million for Q1 2025, Q4 2024, and Q3 2024 respectively.